Japanease

Nov. 10, 2020

Mar. 24, 2021

jRCT2031200193

Phase 1b, Multicenter, Open-label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Pembrolizumab with or without Platinum Chemotherapy in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Phase 1b Study of Dato-DXd in Combination with Pembrolizumab with or without Platinum Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer
(TROPION-Lung02)

Nagao Kiminori

DAIICHI SANKYO Co.,Ltd.

1-2-58, Hiromachi, Shinagawa-ku, Tokyo

+81-3-6225-1111

dsclinicaltrial@daiichisankyo.co.jp

Contact for Clinical Trial Information

DAIICHI SANKYO Co.,Ltd.

1-2-58, Hiromachi, Shinagawa-ku, Tokyo

+81-3-6225-1111

dsclinicaltrial@daiichisankyo.co.jp

Dec. 01, 2020

120

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

treatment purpose

United States/Taiwan/Spain

- Advanced or metastatic NSCLC, histologically confirmed at diagnosis of NSCLC, documented negative test results for EGFR and ALK genomic alterations, and no known genomic alterations in ROS1, NTRK, BRAF, RET, MET, or other driver oncogenes with approved therapies (actionable genomic alterations).
- Documentation of radiological disease progression while on or after receiving the most recent treatment regimen, if any, for advanced or metastatic NSCLC.
- Must meet the following prior therapy requirements for advanced or metastatic NSCLC:
*Dose escalation (all cohorts): Has received <=2 lines of prior anticancer therapy for locally advanced or metastatic NSCLC.
*Dose expansion (cohorts with 4.0 mg/kg or 6.0 mg/kg Dato-DXd in combination with 200 mg fixed dose of pembrolizumab): Has not received PD-1/PD-L1, PD-L2, CTLA-4 directed immunotherapy and may or may not have been treated with systemic chemotherapy for advanced or metastatic NSCLC.
*Dose expansion (cohorts with 4.0 mg/kg or 6.0 mg/kg Dato-DXd in combination with 200 mg fixed dose of pembrolizumab and 4 cycles of AUC 5 carboplatin or cisplatin 75 mg/m^2): Has not been treated with systemic anticancer therapy for advanced or metastatic NSCLC.
- Willing and able to undergo a mandatory tumor biopsy.
- Archival tumor tissue from initial diagnosis, to the extent that archival tumor tissue is available, for measurement of TROP2 expression levels or other biomarkers.
- Has adequate bone marrow reserve and organ function at baseline within 7 days prior to Cycle 1 Day 1

- Experienced grade 3 or higher immune-related adverse events (AEs) with prior treatment of anti-programmed cell death 1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
- Received a live vaccine within 30 days prior to the first dose of study treatment.
- Active, known, or suspected autoimmune disease.
- Concomitant use of chronic systemic (IV or oral) corticosteroids or other immunosuppressive medications, except for managing AEs.
- Prior organ transplantation, including allogeneic tissue or solid organ transplantation.
- Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.
- History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
- Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses.
- Has a history of malignancy, other than NSCLC, except (a) adequately resected non-melanoma skin cancer, (b) curatively treated in situ disease, or (c) other solid tumors curatively treated, with no evidence of disease for >=3 years.

20age old over
No limit

Both

Advanced or Metastatic NSCLC

-Drug: Datopotamab deruxtecan
Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle (starting datopotamab deruxtecan dose of 4.0 mg/kg)
- Drug: Pembrolizumab
Intravenous infusion Q3W on Day 1 of each 21-day cycle (fixed pembrolizumab dose 200 mg Q3W)
- Drug: Carboplatin
Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (AUC 5)
- Drug: Cisplatin
Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (75 mg/mm^2)

Number of Participants with Dose-limiting Toxicities (DLTs) and Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Baseline up to Cycle 1 (Days 1 to 21) for DLTs and up to 28 days after last dose for TEAEs, up to approximately 30 months post-dose ]

1. Objective Response Rate
[Time Frame: Baseline up to BOR (confirmed CR or PR), up to approximately 30 months postdose]
2. Duration of Response
[Time Frame: From first objective response (confirmed CR or PR) to PD or death (whichever occurs first), up to approximately 30 months postdose]
3. Progression-free Survival
[Time Frame: Baseline up PD or death (whichever occurs first), up to approximately 30 months postdose]
4. Overall Survival
[Time Frame: Baseline up to death (any cause), up to approximately 30 months postdose]
5. Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) of Dato-DXd, Total Anti-TROP2 Antibody, and MAAA-1181a
[Time Frame: Cycle 1, Day 1: predose, 30 minutes, 3 hours (h), 5 h, and 7 h postdose; Cycles 1 and 3, Day 2, Day 4, Day 8, and Day 15; Cycles 2-4, Cycle 6, and Cycle 8, Day 1: predose and postdose (each cycle is 21 days)]
6. Pharmacokinetic Parameter Time to Maximum Plasma Concentration (Tmax) of Dato-DXd, Total Anti-TROP2 Antibody, and MAAA-1181a
[Time Frame: Cycle 1, Day 1: predose, 30 minutes, 3 hours (h), 5 h, and 7 h postdose; Cycles 1 and 3, Day 2, Day 4, Day 8, and Day 15; Cycles 2-4, Cycle 6, and Cycle 8, Day 1: predose and postdose (each cycle is 21 days)]
7. Pharmacokinetic Parameter Area Under the Plasma Concentration-Time Curve (AUC) of Dato-DXd, Total Anti-TROP2 Antibody, and MAAA-1181a. Area under the plasma concentration-time curve up to last quantifiable time (AUClast) and area under the plasma concentration-time curve during dosing interval (AUCtau) will be assessed.
[Time Frame: Cycle 1, Day 1: predose, 30 minutes, 3 hours (h), 5 h, and 7 h postdose; Cycles 1 and 3, Day 2, Day 4, Day 8, and Day 15; Cycles 2-4, Cycle 6, and Cycle 8, Day 1: predose and postdose (each cycle is 21 days)]
8. Anti-drug Antibodies for Dato-DXd a and Pembrolizumab
[Time Frame: Baseline up to approximately 30 months postdose]

Recruiting

DAIICHI SANKYO Co.,Ltd.
National Cancer Ctr IRB#2-j
5-1-1 Tsukiji, Chuo-ku, Tokyo

+81-3-3542-2511

Chiken_CT@ml.res.ncc.go.jp
Approval

Nov. 11, 2020

Yes

Plan Description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/ Supporting Documents: - Study Protocol - Statistical Analysis Plan - Clinical Study Report Time Frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication. Access Criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent. URL: https://vivli.org/ourmember/daiichi-sankyo/

NCT04526691
ClinicalTrials.gov